These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32493321)

  • 21. Relationship between neutrophil-lymphocyte ratio and isolated low high-density lipoprotein cholesterol.
    Varol E; Bas HA; Aksoy F; Ari H; Ozaydin M
    Angiology; 2014 Aug; 65(7):630-3. PubMed ID: 23921506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of plasma lipids with white blood cell counts: Results from the Multi-Ethnic Study of Atherosclerosis.
    Lai YC; Woollard KJ; McClelland RL; Allison MA; Rye KA; Ong KL; Cochran BJ
    J Clin Lipidol; 2019; 13(5):812-820. PubMed ID: 31402296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
    Hansel B; Bruckert E
    Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease.
    Liu Z; Fan Q; Wu S; Wan Y; Lei Y
    Lipids Health Dis; 2021 Apr; 20(1):35. PubMed ID: 33874966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.
    Li XL; Guo YL; Zhu CG; Xu RX; Qing P; Wu NQ; Jiang LX; Xu B; Gao RL; Li JJ
    J Am Heart Assoc; 2015 Jan; 4(1):e001412. PubMed ID: 25572484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Value of Non-high-Density Lipoprotein Cholesterol and Neutrophil-Lymphocyte Ratio for Coronary Artery Vulnerable Plaques in Type 2 Diabetes Mellitus.
    Huang X; Yang S; Zhao Q; Chen X; Pan J; Lai S; Ouyang F; Deng L; Du Y; Li X; Hu Q; Guo B; Liu J
    Front Cardiovasc Med; 2022; 9():927768. PubMed ID: 35795369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.
    Zhong Z; Hou J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Lipids Health Dis; 2019 Feb; 18(1):40. PubMed ID: 30711009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal therapy of low levels of high density lipoprotein-cholesterol.
    Kashyap ML; Tavintharan S; Kamanna VS
    Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.
    Liem AH; van de Woestijne AP; Roeters van Lennep HW; Zwinderman AH; van der Steeg WA; Jukema JW
    Curr Med Res Opin; 2008 Feb; 24(2):359-64. PubMed ID: 18081989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
    Stegman B; Shao M; Nicholls SJ; Elshazly M; Cho L; King P; Kapadia S; Tuzcu M; Nissen SE; Puri R
    Atherosclerosis; 2016 Nov; 254():78-84. PubMed ID: 27710808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases.
    Ganjali S; Gotto AM; Ruscica M; Atkin SL; Butler AE; Banach M; Sahebkar A
    J Cell Physiol; 2018 Dec; 233(12):9237-9246. PubMed ID: 30076716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.
    Ballantyne CM; Andrews TC; Hsia JA; Kramer JH; Shear C;
    Am J Cardiol; 2001 Aug; 88(3):265-9. PubMed ID: 11472705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
    Arai H; Hiro T; Kimura T; Morimoto T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Kimura K; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    J Atheroscler Thromb; 2010 Oct; 17(10):1096-107. PubMed ID: 20675955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention.
    Lee EY; Yang Y; Kim HS; Cho JH; Yoon KH; Chung WS; Lee SH; Chang K
    Atherosclerosis; 2018 Dec; 279():1-9. PubMed ID: 30359786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.